Abstract 408P
Background
Sarcomas are a heterogeneous group of uncommon malignancies that are rarely encountered in most general oncology clinics and most general oncologists have very little experience in dealing with them. The Asian Sarcoma Consortium (ASC) is an international study group of oncologists specializing in sarcomas. The group has decided to start a Sarcoma Preceptorship Program. Its goal is increased awareness of the multidisciplinary approach in sarcomas. Objective is to conduct a program evaluation using the first 2 levels of the Kirkpatrick Model, involving Level 1 – focusing on satisfaction surveys of the participants and Level 2 – focusing on amount of information gained through a pre-test and a post-test.
Methods
Activities included didactic lectures, multidisciplinary case discussions and a summative multidisciplinary case presentation at the conclusion. Evaluation was done using satisfaction survey forms and a pre- and post-test. Novartis did their own survey & results were included in analysis, but had no direct participation in conduct of program.
Results
31 persons mostly Oncologists from University/Government Hospitals participated. 50% were consultants. Satisfaction surveys were optimistic, with ASC forms showing high level of satisfaction for the time and scope. Satisfaction level was high when helpfulness of topics was considered. Faculty response showed similar trends. Ratings remained consistent when the Novartis evaluation data were included. Areas for improvement included time management, content, language barriers and inconsistencies in facilitation. Results from pre-test and post-test showed test scores lower in post-test. Coefficient of Test reliability showed that pre-test was highly reliable but not post-test, the causes included external factors like time allotment for the post-test and presence of distractions.
Conclusions
The program was successful in terms of participant and faculty satisfaction. Results were supported by Novartis data. Certain areas for improvement were identified and recommendations were made.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Asian Sarcoma Consortium.
Funding
Asian Sarcoma Consortium Novartis Pharma.
Disclosure
F.Y. Gracieux Jr.: Honoraria (self), RTD Speaker: Roche Philippines; Honoraria (self), Conference Speaker, RTD Speaker: Novartis Philippines; Honoraria (self), Webinar Moderator; RTD Speaker: Boehringer Ingelheim; Honoraria (self), Conference Speaker: GSK Philippines; Honoraria (self), Conference Speaker: Beacon Bangladesh; Honoraria (self), Conference Speaker; RTD Speaker: Roche Malaysia; Honoraria (self), Conference Speaker: Roche Myanmar.
Resources from the same session
490P - Outcomes of sequential epidermal growth factor receptor tyrosine (EGFR) tyrosine kinase inhibitor (TKI) therapy in patients with advanced non-small cell lung carcinoma (NSCLC)- a real-world institutional experience
Presenter: Yvonne Ang
Session: Poster display session
Resources:
Abstract
498P - An observational retrospective study to evaluate the incidence of acquired EGFR T790M resistance in NSCLC patients with EGFR mutation following progression after at least one prior EGFR TKI treatment in Taiwan: ARISE study
Presenter: Shang-gin Wu
Session: Poster display session
Resources:
Abstract
501P - Clinical characteristics and efficacy in non-small cell lung cancer patients with EGFR exon 20 insertion and EGFR amplification
Presenter: Xin Gao
Session: Poster display session
Resources:
Abstract
502P - Epidermal growth factor receptor tyrosine kinase inhibitor treatment response in advanced non-small cell lung cancer with uncommon mutations: A multicenter observational study
Presenter: Masaki Kanazu
Session: Poster display session
Resources:
Abstract
482P - Interim analysis from a phase IIIb, open-label study of afatinib in EGFR TKI-naïve patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC
Presenter: Filippo De Marinis
Session: Poster display session
Resources:
Abstract
483P - A phase IIIb, open-label study of afatinib in EGFR TKI-naïve patients with EGFR mutation-positive NSCLC: A biomarker analysis
Presenter: Rafael Rosell
Session: Poster display session
Resources:
Abstract
484P - Activity of afatinib in patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC and baseline brain metastases: Pooled analysis of three large phase IIIb trials
Presenter: Maya Gottfried
Session: Poster display session
Resources:
Abstract
491P - Clinical outcomes of leptomeningeal metastases in EGFR-mutant lung adenocarcinoma
Presenter: Chia-I Shen
Session: Poster display session
Resources:
Abstract
510P - Paclitaxel as continuation maintenance therapy in patients with advanced non-small cell lung cancer
Presenter: Suzy Gohar
Session: Poster display session
Resources:
Abstract
496P - Higher osimertinib introduction rate achieved by multiple repeated re-biopsy after acquired resistance to first/second generation EGFR-TKIs
Presenter: Taira Ninomaru
Session: Poster display session
Resources:
Abstract